JEOL (6951) Q1 2027 earnings summary

Executive summary

• Q1 FY2026 net sales were ¥24.5 billion, down 39.1% year-over-year, with an operating loss of ¥2.0 billion and a net loss attributable to owners of parent of ¥1,710 million, mainly due to timing of revenue recognition and tighter export controls.

• Results were broadly in line with the initial plan, with business performance remaining on track despite declines.

• Demand in Japan and Asia remained solid, while the US and Europe faced uncertainty from policy and economic conditions.

• Comprehensive income was negative ¥204 million, a significant drop from ¥3,966 million in the previous year.

Financial highlights

• Net sales: ¥24.5 billion (-39.1% YoY); Operating profit: -¥2.0 billion; Net profit: -¥1.7 billion; Gross profit: ¥11,768 million; Gross profit margin: 51.9% (up 0.4pt YoY).

• Basic earnings per share fell to ¥(35.12) from ¥91.32 year-over-year.

• FX impact (yen depreciation) and lower R&D costs partially offset declines from lower sales volume and higher SGA.

• Overseas sales ratio was 68.0%.

• Equity-to-asset ratio improved to 62.3% as of June 30, 2026.

Outlook and guidance

• Full-year and first-half forecasts remain unchanged; full-year net sales forecast is ¥164,000 million, down 8.6% YoY.

• Operating profit is projected at ¥26,500 million, up 1.9% YoY, with profit attributable to owners of parent expected at ¥21,300 million, down 3.6%.

• Continued focus on semiconductors and life sciences as priority growth areas.

• Medium-term plan targets net sales of ¥205.0 billion and operating profit of ¥44.0 billion by FY2029.

• No revisions to previously announced earnings or dividend forecasts.